ESMO 2022 Conference Coverage

 

GYN
08:47

ESMO 2022 Conference Coverage

ESMO 2022 on the SOLO1/GOG-3004 Trial: OS at 7-Year Follow-Up in Patients With Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation Who Received Maintenance Olaparib

FEATURING Paul DiSilvestro
  • 222 views
  • October 3, 2022
  • 2
09:44

ESMO 2022 Conference Coverage

ESMO 2022 on the Randomized Phase 3 FORWARD I Study: Analyses of Patient-Reported Outcomes With Mirvetuximab Soravtansine vs. Standard Chemo in Ovarian Cancer

FEATURING Kathleen Moore
  • 654 views
  • September 27, 2022
  • 2
18:57

ESMO 2022 Conference Coverage

ESMO 2022: Should All Advanced Ovarian Cancer Patients Receive a PARPi in 1L Therapy?

FEATURING David Tan
  • 785 views
  • September 19, 2022
  • 4